News & Updates
Filter by Specialty:
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022Dolutegravir: A better choice for HIV viral suppression in pregnancy?
Among pregnant individuals on antiretroviral therapy (ART) for HIV-1 infection, those on dolutegravir had the greatest viral suppression rates at delivery, a recent US-based observational study showed. However, birth outcomes generally did not differ between dolutegravir recipients and those on various other ART regimens.
Dolutegravir: A better choice for HIV viral suppression in pregnancy?
13 Nov 2022Once-weekly semaglutide safe, effective in type 2 diabetes patients
Initiating a once-weekly treatment regimen of semaglutide helps control glycated haemoglobin (HbA1c) levels and body weight in patients with type 2 diabetes, without introducing new safety concerns, a Japan study has found.
Once-weekly semaglutide safe, effective in type 2 diabetes patients
13 Nov 2022Immune response to flu shots preserved in seniors with well-controlled metabolic comorbidities
Older adults with well-controlled metabolic comorbidities exhibit immune response to influenza vaccine, as shown in the results of the DYNAMIC study. Notably, physical activity further increases immune response particularly for influenza A/H3N2.